Navigation Links
ACD Completes the Second Closing of Series A Financing and Initiates Services for Biomarker Validation and Companion Diagnostic Development
Date:9/2/2009

HAYWARD, Calif., Sept. 2 /PRNewswire/ -- Advanced Cell Diagnostics, Inc. (ACD), announced today that it has completed the second closing of its Series A equity financing from Morningside Ventures, bringing the total capital raised in this round to $5.4 million.

ACD will use the funds to accelerate the development of its proprietary diagnostic tests based on the company's patent pending RNAscope(TM) technology. "This second closing marks the achievement of our RNAscope(TM) technology development milestones, including in situ detection of single RNA molecules in blood and FFPE tissues, multiplex analysis, and full assay automation," said Dr. Yuling Luo, Founder, President and CEO of ACD. "We can now offer our world class assay development expertise in RNA analysis for biomarker validation and companion diagnostic development in partnership with pharmaceutical and biotechnology companies."

"We are pleased to be in partnership with ACD and are excited about the tremendous potential of RNAscope(TM) technology. ACD has made impressive and speedy progress in RNAscope(TM) technology development, achieving all of its milestones," commented Morningside co-founder, Dr. Gerald Chan. "RNAscope(TM) technology has great promise to shorten the path to targeted therapeutic development, hastening fulfillment of the vision of personalized medicine."

About Advanced Cell Diagnostics (www.acdbio.com)

Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. The company's products and services are based on its proprietary RNAscope(TM) technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases. These partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners' targeted therapeutics. ACD also pursues internal programs to develop proprietary diagnostic tests in cancer management.

About Morningside

Morningside is a diversified investment group founded in 1986 by the Chan family of Hong Kong. It is engaged primarily in private equity and venture capital investments. The group has investments in North America, Europe, across Asia-Pacific, and since 1992, in Mainland China. Morningside was one of the earliest institutional investors in China's internet industry and in recent years has been an active investor in China's emerging biotechnology sector.


'/>"/>
SOURCE Advanced Cell Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pacific Biometrics Completes $4 Million Debt Financing
2. Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro
3. Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009
4. Cephalon Completes Acquisition of Arana Therapeutics
5. Cardinal Health Completes Biotech Acquisition
6. Beckman Coulter Completes Acquisition of Olympus Lab-Based Diagnostics Business
7. Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
8. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
9. GlaxoSmithKline Completes Acquisition of Stiefel
10. Oncolytics Biotech(R) Inc. Completes Lyophilization Process for REOLYSIN(R)
11. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
Breaking Biology Technology:
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
Breaking Biology News(10 mins):